



University Industry
Demonstration Partnership

Academic Medical Center-Industry Engagement Project Working with Industry Compliance

Speaker Biographies*



**Mark Breedlove
Vice President and Global Leader
Peripheral Interventional Division
Cook Medical**

Mark Breedlove, a 23-year veteran of Cook Medical, is vice president and global leader for the Peripheral Interventional (PI) division. PI is Cook's largest clinical division, serving customers and patients across more than 135 countries worldwide.

Mark has been an integral part of PI's growth over the years. He has served in several roles, including as regional manager and national sales manager. In 2009, he assumed responsibility for leading PI's global marketing and product management teams. He was promoted to vice president in 2014.

The Carmel, Ind., resident obtained a bachelor's degree in chemistry from Indiana University as well as an IU Business Foundation Certificate.

*** No compensation, in any form, was paid to any of the speakers in this module.**



Anantha Shekhar, MD, PhD
Executive Associate Dean for Research
August M. Watanabe Professor of
Medical Research
Professor of Psychiatry
Professor of Neurobiology and
Pharmacology & Toxicology
Indiana University School of Medicine

Dr. Shekhar is the Executive Associate Dean for Research, the August M. Watanabe Professor of Medical Research, Professor of Psychiatry, Professor of Neurobiology and Pharmacology & Toxicology at the Indiana University School of Medicine. Dr. Shekhar is also the founding Director of the Indiana Clinical and Translational Sciences Institute (CTSI), a statewide institute within the Indiana University School of Medicine, supported by a CTSA grant from the US National Institutes of Health, and established in 2008 as a joint partnership between Indiana, Purdue and Notre Dame Universities. He has served in many leadership roles in managing clinical services and research programs in psychiatry and has been continuously funded by the National Institutes of Health for his basic, clinical and translational research since 1989. He has authored more than 200 peer reviewed publications.

Currently, in addition to his role in leading the statewide translational research initiative, Dr. Shekhar leads a successful basic and clinical research programs in the areas of stress, anxiety and neuropsychiatric disorders. A number of grants from the National Institutes of Health, private foundations, and commercial collaborations currently support his research. He has also founded a biotechnology company Anagin that is successfully developing novel treatments for post-traumatic stress disorder, traumatic brain injury and related neuropsychiatric disorders. He has received several university and national awards and has been a member and chair of several NIH study sections. He has also served as a member of the Board of Scientific Advisors for the National Institute of Mental Health. He is also the immediate past-president of the Society of Clinical and Translational Sciences and the Association for Clinical and Translational Sciences. He currently serves as a tenured a member of the Advisory Board for Clinical Research at the Clinical Center at NIH and will taking over as the chair of that Board in 2016. He has also been appointed to serve as a member of the Advisory Council for National Center for Advancing Translation Sciences (NCATS) of the NIH and a member of the Board of Governors for the Cures Acceleration Network (CAN) at the NIH.



William M. Pierce, Jr., PhD
Executive Vice President for Research
and Innovation
University of Louisville

William M. Pierce, Jr. serves as the Executive Vice President for Research and Innovation at the University of Louisville. He received the baccalaureate in chemistry in 1977 and the PhD in pharmacology and toxicology in 1981 from the University of Louisville. He then worked as a postdoctoral scholar at Stanford University in molecular pharmacology, followed by work as a research associate in pharmacology and toxicology at the University of Louisville.

In 1985, Dr. Pierce joined the faculty of the University of Louisville and is currently professor of pharmacology and toxicology and professor of chemistry. In this capacity, he has taught students at the postgraduate, graduate, professional and undergraduate levels in eight of the schools and colleges of the university. His research areas of emphasis include (1) drug design and organ targeting of pharmaceuticals and (2) biomolecular mass spectrometry with emphasis on proteomics. He holds eight U.S. patents and was awarded two of the President's Distinguished Faculty Awards, one in Research and one in Service.

Dr. Pierce founded the university's Blood Lead Monitoring Laboratory in 1992 and the Biomolecular Mass Spectrometry Laboratory in 1996. He served as the Chair of the university Faculty Senate (2004-2006) and has served on the Board of Trustees, the UofL Research Foundation Board, the Alumni Board of Directors and the UofL Athletic Association Board. He has held administrative posts as Vice Provost for Graduate Affairs, Interim Dean of the School of Interdisciplinary and Graduate Studies, and Executive Vice President for Research and Innovation.

In 2005, Dr. Pierce and his colleagues K. Grant Taylor and Leonard C. Waite founded Pradama Inc., a specialty pharmaceutical company focused on the development and commercialization of products to treat bone diseases, including osteoporosis, osteomyelitis and bone metastases.